Results 211 to 220 of about 182,433 (270)
Some of the next articles are maybe not open access.
Treatment with Interferons (including Pegylated Interferons) in Patients with Hepatitis B
Seminars in Liver Disease, 2004Studies of 4 to 6 months of treatment with interferon for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection have shown clearance of HBeAg to be higher in treated patients than it is in controls by approximately 25%. These results are considerably better than those with antiviral agents.
exaly +5 more sources
Journal of Dermatology, 2011 Pegylated or non-pegylated alpha-interferon are frequently used medications for the treatment of both chronic hepatitis B and chronic hepatitis C. Skin disorders, which are mainly comprised of eczematous dermatitis, are frequently seen during treatment ...
Özgür Günal, Şener Barut
exaly +2 more sources
Clinics in Liver Disease, 2003
In summary, pegylated IFNs have a longer half-life, reduced immunogenicity, better pharmacokinetics, and enhanced biological activity when compared with standard IFN. Better adherence rates are feasible because of the once weekly administration of pegylated IFN. The adverse event profile is largely comparable. The improved pharmacokinetics of pegylated
Umaprasanna S, Karnam, K Rajender, Reddy
openaire +4 more sources
In summary, pegylated IFNs have a longer half-life, reduced immunogenicity, better pharmacokinetics, and enhanced biological activity when compared with standard IFN. Better adherence rates are feasible because of the once weekly administration of pegylated IFN. The adverse event profile is largely comparable. The improved pharmacokinetics of pegylated
Umaprasanna S, Karnam, K Rajender, Reddy
openaire +4 more sources
Pegylated interferons for chronic hepatitis B
Antiviral Research, 2003Conventional interferon therapy has been used for the treatment of chronic hepatitis B (CHB) for many decades. However, the use of interferon has been limited by its short half-life and high incidence of dose-related side effects. A meta-analysis investigating the short- and long-term consequences of interferon therapy showed that, whilst interferon ...
Craxi, A., Cooksley, W. G.
openaire +4 more sources
Journal of Neuroscience Nursing, 2014
Most multiple sclerosis (MS) therapies are injectable drugs, and the frequency of injections has been shown to be inversely proportional to overall compliance. One method of improving therapeutic compliance and thus clinical outcomes is to develop medications that require less frequent dosing. One of the most promising modification techniques to extend
Anne, Howley, Marcelo, Kremenchutzky
openaire +2 more sources
Most multiple sclerosis (MS) therapies are injectable drugs, and the frequency of injections has been shown to be inversely proportional to overall compliance. One method of improving therapeutic compliance and thus clinical outcomes is to develop medications that require less frequent dosing. One of the most promising modification techniques to extend
Anne, Howley, Marcelo, Kremenchutzky
openaire +2 more sources
Use of pegylated interferon in hypereosinophilic syndrome
Leukemia Research, 2012Scant information exists about pegylated interferons (PEG-IFNs) use for treating hypereosinophilic syndrome (HES). We describe 6 patients with HES-1 patient with a newly identified chromosomal abnormality-who received PEG-IFNs. PEG-IFN alpha-2b replaced interferon (IFN) alpha-2b for 4 patients and was initial treatment of 2 patients.
Joseph H, Butterfield +1 more
openaire +2 more sources
Sylatron: A Pegylated Interferon for Use in Melanoma
Annals of Pharmacotherapy, 2012OBJECTIVE: To review the currently available literature on peginterferon alfa-2b (pegIFN [Sylatron]), including its role in therapy and toxicity for adjuvant treatment of locally advanced melanoma. DATA SOURCES: A literature search was
Jai N, Patel, Christine M, Walko
openaire +2 more sources
Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C
Journal of Controlled Release, 2001Poly(ethyleneglycol) or PEG has proven to be of great value for a range of biomedical applications. A review the properties of PEG that lead to these applications is reported. Emphasis is placed on pharmaceutical uses of PEG--proteins, with specific discussion of the attributes of PEGylated alpha-interferon for treatment of hepatitis C.
A, Kozlowski, J M, Harris
openaire +2 more sources
Pharmacokinetics of pegylated interferons: What is misleading?
Digestive and Liver Disease, 2004Available pegylated interferon (PEG-IFN) products confer enhanced therapeutic efficacy when compared with their IFN counterparts, and the added convenience of once-weekly dosing with no novel toxicities. PEG optimises the action of the IFNs by decreasing clearance rates, thereby allowing serum concentrations to remain constant over the dosing period ...
openaire +3 more sources